Lebrikizumab eased itch and pain in patients with hand and foot eczema, according to new findings presented under the ADtouch banner and reported by HCPLive.

That single result matters more than it first looks. Hand and foot involvement is one of the most treatment-resistant presentations of atopic dermatitis — it's where patients feel symptoms most, because they use their hands and walk on their feet all day.

What did the ADtouch analysis actually measure?

The data connect to lebrikizumab, an IL-13 inhibitor already established in atopic dermatitis. The ADtouch findings zero in on two symptoms patients rank as most burdensome: itch and pain, specifically at the hands and feet.

Itch is the defining complaint of atopic dermatitis. Pain, though, is what hand and foot disease adds — cracked, fissured skin on palms and soles turns everyday tasks into ordeals. A therapy that moves both endpoints in these locations answers a question clinicians ask constantly in the exam room.

Why hand and foot disease gets its own scrutiny

Clinicians know the pattern. A patient can clear trunk and limbs on systemic therapy while palms and soles lag behind, and that residual disease drives more quality-of-life damage than a higher body surface area elsewhere. Painful fissures limit work — particularly for patients in manual jobs — and itch at night disrupts the sleep that already suffers in atopic dermatitis.

So a symptom-focused readout like ADtouch's, centered on itch and pain rather than a global severity score alone, tracks what patients actually report.

What does this change for dermatology practice?

For now, it strengthens the case that IL-13 blockade with lebrikizumab addresses the symptom burden of atopic dermatitis in the sites patients feel most. Itch and pain relief in hand and foot disease is the outcome that predicts whether a patient keeps their job, sleeps through the night, and stays on therapy — the practical endpoints behind adherence.

As HCPLive reported the findings, the emphasis lands squarely on symptom improvement in these hard-to-treat areas, adding a location-specific data point to lebrikizumab's atopic dermatitis evidence base.

Further detail — cohort size, study design, and magnitude of symptom change — will determine how the ADtouch results translate into treatment selection for the hand-and-foot subgroup. Dermatologists will want the full presentation data before reordering their systemic algorithm.

The ADtouch findings position lebrikizumab as a therapy with expanding, symptom-centered evidence in atopic dermatitis' most function-limiting presentations.